Key result
Angiotensin receptor blockers (valsartan or fimasartan) lowered central systolic blood pressure compared to atenolol in ischemic stroke patients.
Why the study?
Do angiotensin receptor blockers (valsartan or fimasartan) improve central and cerebral haemodynamic parameters compared to atenolol in hypertensive patients with ischaemic stroke?
RCT (n=105)
Double-blind
1:1:1 ratio, computer generated block card
No
Do angiotensin receptor blockers (valsartan or fimasartan) improve central and cerebral haemodynamic parameters compared to atenolol in hypertensive patients with ischaemic stroke?
Short-term ARB administration effectively reduces central pressure and dampens cerebral pulsatility compared to atenolol in hypertensive patients with ischemic stroke.
Answers are grounded in this paper and cite their sources.
Supports ARB preference over atenolol for central BP control in ischemic stroke; extends brachial BP trials to central hemodynamics.
Central and cerebral haemodynamic parameters can vary under similar brachial blood pressure (BP). We aimed to investigate the effects of antihypertensive agents on central and cerebral haemodynamic parameters in hypertensive patients with ischaemic stroke. The Fimasartan, Atenolol, and Valsartan On haemodynamic paRameters (FAVOR) study was conducted in a prospective, double-blinded manner. One hundred five patients were randomly administered atenolol, valsartan, or fimasartan during 12 weeks. We measured brachial, central, cerebral haemodynamic parameters and plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) levels at baseline and after 12-week. Baseline haemodynamic parameters were balanced among the three groups. Even with similar brachial BP reduction, significantly lower central systolic BP (atenolol; 146.5 ± 18.8 vs. valsartan; 133.5 ± 20.7 vs. fimasartan; 133.6 ± 19.8 mmHg, p = 0.017) and augmentation index values (89.8 ± 13.2 vs. 80.6 ± 9.2 vs. 79.2 ± 11.6%; p = 0.001) were seen in the angiotensin receptor blockers (ARBs) groups. The pulsatility index on transcranial Doppler was significantly reduced in valsartan (p = 0.002) and fimasartan group (p = 0.008). Plasma NT-proBNP level was also significantly decreased in ARB groups, especially for the fimasartan group (37.8 ± 50.6 vs. 29.2 ± 36.9 vs.19.2 ± 27.8 pg/mL; p = 0.006). These findings suggest that short-term ARB administration would be favourable for ischaemic stroke patients with hypertension, permitting effective reduction of central pressure and dampening of cerebral pulsatility.
No takes yet. Share an insight, caveat, or question.
Choi et al. (2018) conducted an RCT in Ischaemic stroke with hypertension (n=105). Valsartan or Fimasartan (Angiotensin receptor blockers) vs. Atenolol 50 mg was evaluated on Difference in central systolic blood pressure among the three groups after 12 weeks of treatment (p=0.017). Angiotensin receptor blockers (valsartan or fimasartan) lowered central systolic blood pressure compared to atenolol in ischemic stroke patients.
Synapse has enriched 10 related papers. Consider them for comparative context: